88 completed. 88 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 88 | Completed 88 |
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease Memantine, Memantine Oral Tablet - Alzheimer Disease | Phase 4 | Completed | Carnot Laboratories | 105 | 2024-10-04 | 2026-02-18 |
| Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia Spironolactone, Placebo - Mild Cognitive Impairment, Alzheimer Disease | Phase 4 | Completed | Emory University | 25 | 2022-09-06 | 2026-10-30 |
| Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical Trial Usual Care, WATER+CT - Mild Cognitive Impairment | Phase 4 | Completed | VA Office of Research and Development | 121 | 2022-01-03 | 2026-09-14 |
| Monitoring Anti-Dementia Drugs by Serum Levels Donepezil, Memantine, Measurement of serum level of anti-dementia drug - Dementia, Dementia With Lewy Bodies | Phase 4 | Completed | Zealand University Hospital | 132 | 2020-02-04 | 2025-02-10 |
| Trial of Parkinson's And Zoledronic Acid Zoledronic Acid 5Mg/Bag 100Ml Inj, Placebo - Parkinson Disease, Osteoporosis | Phase 4 | Completed | California Pacific Medical Center Research Institute | 2721 | 2019-11-15 | 2026-06-25 |
| A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. Methylphenidate Extended Release Oral Capsule, Placebo - Alzheimer Dementia | Phase 4 | Completed | Massachusetts General Hospital | 11 | 2019-11-01 | 2023-06-02 |
| Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) Suvorexant, Zolpidem, Placebo oral capsule - Progressive Supranuclear Palsy(PSP), Insomnia | Phase 4 | Completed | University of California, San Francisco | 40 | 2019-06-02 | 2026-09-01 |
| Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease Memantine - Alzheimer Disease | Phase 4 | Completed | University of California, San Diego | 53 | 2019-01-31 | 2026-04-16 |
| A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. Rivastigmine - Alzheimer's Disease | Phase 4 | Completed | Novartis Pharmaceuticals | 100 | 2018-12-31 | 2024-05-31 |
| Lithium As a Treatment to Prevent Impairment of Cognition in Elders Lithium Carbonate, Placebo oral capsule - Mild Cognitive Impairment | Phase 4 | Completed | Ariel Gildengers, MD | 83 | 2018-02-02 | 2025-09-11 |
| NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. Rivastigmine Patch - Mild to Moderate Alzheimer's Disease | Phase 4 | Completed | Novartis Pharmaceuticals | 118 | 2016-05-09 | 2019-09-12 |
| Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease Donepezil - Alzheimer's Disease | Phase 4 | Completed | Beijing Friendship Hospital | 241 | 2016-04-01 | 2024-08-23 |
| Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease Acetyl-L-Carnitine, Placebo of Acetyl-L-Carnitine - Alzheimer Disease | Phase 4 | Completed | Dong-A ST Co., Ltd. | 265 | 2016-04-01 | 2021-04-14 |
| Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer Memantine (once daily), Memantine (twice daily) - Alzheimer Dementia (AD) | Phase 4 | Completed | H. Lundbeck A/S | 62 | 2015-10-01 | 2019-03-14 |
| Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Neuraceq (florbetaben 18F), PET - Alzheimer's Disease (AD) | Phase 4 | Completed | Lantheus Biosciences Ltd. | 218 | 2015-10-01 | 2026-10-09 |
| Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Rivastigmine - Alzheimer Disease, CVA (Cerebrovascular Accident) | Phase 4 | Completed | National Neuroscience Institute | 100 | 2015-04-01 | 2021-03-05 |
| 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients ENA713 - Alzheimer's Disease | Phase 4 | Completed | Novartis Pharmaceuticals | 222 | 2014-08-01 | 2017-02-13 |
| Efficacy of Pain Treatment on Depression in Patients With Dementia Paracetamol, Buprenorphine, Paracetamol placebo - Depression, Pain | Phase 4 | Completed | University of Bergen | 163 | 2014-08-01 | 2017-04-04 |
| Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia Neurostar repetitive transcranial magnetic stimulator - Apathy, Alzheimer's Dementia | Phase 4 | Completed | Central Arkansas Veterans Healthcare System | 20 | 2014-05-01 | 2019-08-21 |
| Evaluation of Reader Training Processes florbetapir F 18 - Alzheimer's Disease | Phase 4 | Completed | Avid Radiopharmaceuticals | 241 | 2014-03-01 | 2015-09-28 |
Showing 20 of 88. Sign in to see all of them.
Alzheimer Disease (86) · Dementia (21) · Cognitive Dysfunction (9) · Psychomotor Agitation (7) · Psychotic Disorders (4) · Cognition Disorders (3) · Depression (3) · Lethargy (3) · Lewy Body Disease (3) · Plaque, Amyloid (3) · Aggression (2) · Anosmia (2) · Behavior (2) · Dementia, Vascular (2) · Memory Disorders (2)
Brain Diseases (88) · Central Nervous System Diseases (88) · Nervous System Diseases (88) · Neurodegenerative Diseases (88) · Mental Disorders (87) · Neurocognitive Disorders (86) · Dementia (66) · Pathological Conditions, Signs and Symptoms (21) · Neurologic Manifestations (18) · Signs and Symptoms (18) · Neurobehavioral Manifestations (14) · Behavior (11) · Behavioral Symptoms (10) · Aberrant Motor Behavior in Dementia (7)
Memantine (18) · Donepezil (16) · Rivastigmine (12) · Escitalopram (4) · Galantamine (4) · Risperidone (4) · florbetapir (4) · Methylphenidate (3) · Lithium Carbonate (2) · Olanzapine (2) · Simvastatin (2) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · AC-1202 (1) · Acetaminophen (1) · Acetylcarnitine (1)
Novartis (7) · Novartis Pharmaceuticals (7) · Avid Radiopharmaceuticals (4) · New York State Psychiatric Institute (4) · Eisai Inc. (3) · Eisai Korea Inc. (3) · NYU Langone Health (3) · VA Office of Research and Development (3) · Emory University (2) · Forest Laboratories (2) · H. Lundbeck A/S (2) · Janssen Korea, Ltd., Korea (2) · Johns Hopkins University (2) · Sunnybrook Health Sciences Centre (2) · Abarbanel Mental Health Center (1)
United States (44) · South Korea (8) · France (5) · Canada (4) · China (4) · Japan (3) · Australia (2) · Israel (2) · Norway (2) · Spain (2) · Argentina (1) · Brazil (1) · Denmark (1) · Germany (1) · India (1)
Davangere Devanand, M.D. (3) · Adrian Leibovici MD (1) · Alberto Mimenza Alvarado, Dr. (1) · Andrea Snow, PhD MS BS (1) · Ane Erdal, PhD candidate (1) · Antoine Trammell, MD, MPH (1) · Ariel Gildengers, MD (1) · Barry Reisberg, M.D. (1) · Bruce G. Pollock, MD, PhD (1)
PMID 33189083, PMID 10511011, PMID 10588403, PMID 10913502, PMID 11072948, PMID 16494088, PMID 17183151, PMID 18198262, PMID 18251622, PMID 18591575, PMID 19210951, PMID 19389332, PMID 19874395, PMID 20220576, PMID 20429946, PMID 21062616, PMID 21274364, PMID 21476613, PMID 21561398, PMID 21645184, PMID 21845596, PMID 22269160, PMID 22813231, PMID 23075176, PMID 23218100, PMID 23429813, PMID 24144505, PMID 24290367, PMID 25523430, PMID 26876309, PMID 27780331, PMID 27855483, PMID 28945120, PMID 29107051, PMID 29487556, PMID 29635383, PMID 29725986, PMID 29854939, PMID 30761509, PMID 31985467, PMID 32333591, PMID 32925060, PMID 33308285, PMID 33649343, PMID 35104057, PMID 37271721, PMID 37353809, PMID 39498781, PMID 40034344, PMID 40501510
2004 (1), 2015 (1), 2017 (1), I01RX003143 (1), R01AG018487 (1), R01AG021488 (1), R01AG041795 (1), R01AG055389 (1), R01AG059417 (1), R01MH043832 (1), R01MH055735 (1), R01MH056511 (1), R01MH071536 (1), R21MH061801 (1)